Saturday, 31 October 2026European Markets

THUNDERBIRD Stock Is 32% Up In The Last 21 Sessions

Loading stream...

Thunderbird Resorts Inc. (AEX-Index: TBIRD.AS) shares have been making waves in the stock market. In a period of just 21 trading sessions, there was an astounding 32.45% gain, with the shares increasing from EUR0.08 to EUR0.10 as of Tuesday morning trading. Interestingly, this rise followed a downward trend in the previous session, signaling a remarkable turnaround in Thunderbird's performance.

About Thunderbird Resorts

Based in Panama, Thunderbird Resorts is a company that has diversified into gaming, hospitality and real estate. It has a significant presence across Nicaragua and Peru, where it operates three slot parlors and three casinos, and has 630 gaming positions. The company also runs operations across those three regions.

Financial Performance

Despite TBIRD.AS's impressive performance, it's important to take a closer look at its fundamentals. Thunderbird boasts a trailing 12-month Earnings per Share of EUR0.01, signifying modest profitability. Its PE (Price to Earnings) Ratio stands at 10.2, suggesting that an investor is investing EUR10.2 for every euro earned. This high PE Ratio may be an indication that investors anticipate more growth from Thunderbird in the future.

Trading Volume

Thunderbird last reported a trading volume of 216,922 shares. This figure is an indication of diminished trading interest over recent times, which is a trend to closely observe.

Emerging Player in the Market

As the AEX-Index, where TBIRD.AS is listed, continues to decline by 0.08% to EUR772.13, it is important for investors to keep an eye on this emerging player in the gaming and hospitality industries. Thunderbird's ability to buck trends during its current bull run is notable. It underscores the often volatile nature of stock markets and at the same time, the possible rewards of investing despite the associated risks.

More news about THUNDERBIRD (TBIRD.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com